Thrombolytic Agents: A Perspective
Authors: Edward Genton, Liberto Pechet
Journal: Annals of Internal Medicine (1968)

Editorials1 September 1968Thrombolytic Agents: A PerspectiveEDWARD GENTON, M.D., F.A.C.P., LIBERTO PECHET, M.D.EDWARD GENTON, M.D., F.A.C.P.Search for more papers by this author, LIBERTO PECHET, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-69-3-625 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe feasibility of dissolving intravascular fibrin deposits by enzymatic means (thrombolysis) appears established, and the prospect of clinical use of this method has stimulated efforts to develop suitable agents. An ideal thrombolytic agent would have various properties, including effectiveness, safety, nonantigenicity, availability, and simplicity of use. Necessarily, such agents would regularly produce thrombolysis in a variety of thromboembolic states, resulting in restoration of circulation to involved areas, preservation of tissue viability, and reversal of the hemodynamic consequences of vascular thrombosis. A predictable degree of activity would be producible without creating adverse effects such as hypotension, febrile reactions, or coagulation alterations....Bibliography Editorial: Anticoagulation recidivans. New Eng. J. Med. 278: 1231, 1968. CrossrefMedlineGoogle Scholar BERGKVIST R and SVARD PO: Studies on the thrombolytic activity of a protease from Aspergillus oryzae. Acta Physiol. Scand. 60: 363, 1964. CrossrefMedlineGoogle Scholar FEARNLEY GR: Fibrinolysis, Edward Arnold, London, 1965, p. 191. Google Scholar FLETCHER AP, ALKJAERSIG N, and SHERRY S: Assay of thrombolytic ("fibrinolytic") mixtures intended for therapeutic use. J. Lab. Clin. Med. 57: 620, 1961. MedlineGoogle Scholar FLETCHER AP, ALKJAERSIG N, SHERRY S, GENTON E, HIRSH J, and BUCHANAN F: The development of urokinase as a thrombolytic agent. Maintenance of a sustained thrombolytic state in man by its intravenous injection. J. Lab. Clin. Med. 65: 713, 1965. MedlineGoogle Scholar FLETCHER AP and SHERRY S: Thrombolytic agents. Ann. Rev. Pharmacol. 6: 89, 1966. CrossrefMedlineGoogle Scholar KARACA M, STEFANINI M, and MELE R: Fibrinolysis. VII. Clot lysis, coagulation, and fibrinolytic mechanisms after administration of aspergillin O (mold fibrinolysin) in man. J. Lab. Clin. Med. 59: 799, 1962. MedlineGoogle Scholar KORTGE P, PRAETORIUS F, SCHNEIDER B, HECKNER F, VAN DE LOO J, PEZOLD FA, POLIWODA H, SCHMUTZLER R, and ZEKORN D The thrombolytic therapy of recent myocardial infarction. German Med. Monthly 13: 111, 1968. MedlineGoogle Scholar ROSCHLAU WH: Thrombolytic therapy with CA-7. A fibrinolytic enzyme from Aspergillus oryzae. Canad. Med. Ass. J. 98: 757, 1968. MedlineGoogle Scholar ROSCHLAU WH and FISHER AM: Thrombolytic therapy with local perfusions of CA-7 (fibrinolytic enzyme from aspergillus oryzae) in the dog. Angiology 17: 670, 1966. CrossrefMedlineGoogle Scholar SHERRY S: Urokinase. Ann. Intern. Med. 69: 415, 1968. LinkGoogle Scholar VON KAULLA KN: Nonenzymatic activation of the fibrinolytic enzyme system. Fed. Proc. 25: 57, 1966. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: EDWARD GENTON, M.D., F.A.C.P.; LIBERTO PECHET, M.D. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byFibrinolytic properties of basidiomycetes Coprinus lagopides and Funalia trogiiFungal ProteasesObservations in anticoagulant and thrombolytic therapy in pulmonary embolismThrombolytic Therapy and Fatal Massive Pulmonary EmboliJERZY GAJEWSKI, M.D., PH.D. 1 September 1968Volume 69, Issue 3Page: 625-628KeywordsFibrinHemodynamicsHypotensionSafetyThrombosis ePublished: 1 December 2008 Issue Published: 1 September 1968 PDF downloadLoading ...